Bill Title: Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.

Sponsorship: Bipartisan Bill

Status: (Passed) 2023-05-27 - Effective on . . . . . . . . . . . . . . . September 1, 2024 [SB241 Detail]

Text: Latest bill text (Enrolled) [HTML]

---

PolitiCorps Conversations

Start PolitiCorps Debate

Title	PolitiCorps	Access	Comments	Views	Last Post
There are no visible public or private PolitiCorps discussions concerning the 2023 Texas SB241 at this time.